N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide

N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide 구조식 이미지
카스 번호:
633698-99-4
상품명:
N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide
동의어(영문):
LF220542;LF-220542;LF22-0542;LF 220542;LF 22-0542;Safotibant;LF-22-0542;N-(4-(4,5-Dihydro-1H-imidazol-2-yl)benzyl)-2-(2-(4-methoxy-N,2,6-trimethylphenylsulfonamido)ethoxy)-N-methylacetamide;N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide;Acetamide, N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]-N-methyl-
CBNumber:
CB34810147
분자식:
C25H34N4O5S
포뮬러 무게:
502.62626
MOL 파일:
633698-99-4.mol

N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide 속성

끓는 점
680.4±65.0 °C(Predicted)
밀도
1.23±0.1 g/cm3(Predicted)
산도 계수 (pKa)
9.92±0.40(Predicted)

안전

N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide C화학적 특성, 용도, 생산

용도

Safotibant is a reagent with pharmocological activity to inhibited retinal inflammation and oxidative stress in rat with Zanosar induced diabetes

N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide 준비 용품 및 원자재

원자재

준비 용품


N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide 공급 업체

글로벌( 2)공급 업체
공급자 전화 이메일 국가 제품 수 이점
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
TargetMol Chemicals Inc. 4008200310
marketing@tsbiochem.com China 24017 58

Copyright 2019 © ChemicalBook. All rights reserved